S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in

Axonics Modulation Technologies Stock Forecast, Price & News

+0.50 (+0.95 %)
(As of 02/24/2021 12:00 AM ET)
Today's Range
Now: $52.87
50-Day Range
MA: $53.26
52-Week Range
Now: $52.87
Volume588,673 shs
Average Volume529,627 shs
Market Capitalization$2.10 billion
P/E RatioN/A
Dividend YieldN/A
Axonics Modulation Technologies, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems in the United States and internationally. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence, and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was incorporated in 2012 and is based in Irvine, California.


Axonics Modulation Tech Earnings Preview
February 24, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:AXNX
Year FoundedN/A



Sales & Book Value

Annual Sales$13.82 million
Book Value$6.40 per share


Net Income$-79,930,000.00


Market Cap$2.10 billion
Next Earnings Date2/25/2021 (Confirmed)
OptionableNot Optionable


Overall MarketRank

1.52 out of 5 stars

Medical Sector

412th out of 1,958 stocks

Surgical & Medical Instruments Industry

39th out of 168 stocks

Analyst Opinion: 2.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.50 (+0.95 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXNX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Axonics Modulation Technologies (NASDAQ:AXNX) Frequently Asked Questions

Is Axonics Modulation Technologies a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics Modulation Technologies in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Axonics Modulation Technologies stock.
View analyst ratings for Axonics Modulation Technologies
or view top-rated stocks.

What stocks does MarketBeat like better than Axonics Modulation Technologies?

Wall Street analysts have given Axonics Modulation Technologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Axonics Modulation Technologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Axonics Modulation Technologies' next earnings date?

Axonics Modulation Technologies is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Axonics Modulation Technologies

How were Axonics Modulation Technologies' earnings last quarter?

Axonics Modulation Technologies, Inc. (NASDAQ:AXNX) posted its earnings results on Monday, November, 9th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.28. The business earned $35.24 million during the quarter, compared to analyst estimates of $22.95 million. Axonics Modulation Technologies had a negative net margin of 76.62% and a negative trailing twelve-month return on equity of 28.05%. Axonics Modulation Technologies's revenue was up 2592.4% on a year-over-year basis. During the same period last year, the firm earned ($0.89) EPS.
View Axonics Modulation Technologies' earnings history

How has Axonics Modulation Technologies' stock been impacted by Coronavirus?

Axonics Modulation Technologies' stock was trading at $30.22 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXNX stock has increased by 75.0% and is now trading at $52.87.
View which stocks have been most impacted by COVID-19

What guidance has Axonics Modulation Technologies issued on next quarter's earnings?

Axonics Modulation Technologies issued an update on its FY 2020 After-Hours earnings guidance on Monday, January, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $111.5-111.5 million, compared to the consensus revenue estimate of $112.31 million.

What price target have analysts set for AXNX?

8 analysts have issued 12 month price targets for Axonics Modulation Technologies' stock. Their forecasts range from $48.00 to $77.00. On average, they expect Axonics Modulation Technologies' share price to reach $61.00 in the next twelve months. This suggests a possible upside of 15.4% from the stock's current price.
View analysts' price targets for Axonics Modulation Technologies
or view top-rated stocks among Wall Street analysts.

Who are Axonics Modulation Technologies' key executives?

Axonics Modulation Technologies' management team includes the following people:
  • Mr. Raymond W. Cohen, CEO & Director (Age 62, Pay $871.2k)
  • Mr. Danny L. Dearen, Pres & CFO (Age 58, Pay $636.2k)
  • Mr. Rinda K. Sama, Chief Operating Officer (Age 42, Pay $536.2k)
  • Mr. Guangqiang Jiang Ph.D., Chief Technology Officer (Age 48)
  • Mr. Neil Bhalodkar, VP of Investor Relations
  • Mr. Aaron Pettit, Gen. Counsel & Chief Compliance Officer
  • Mr. John Woock Ph.D., Chief Marketing Officer (Age 38)
  • Mr. Michael V. Williamson, Sr. VP, Gen. & IP Counsel (Age 50)
  • Dr. Karen L. Noblett M.D., M.A.S., Chief Medical Officer (Age 58)
  • Mr. Prabodh Mathur, Chief Product Devel. Officer (Age 61)

What is Raymond W. Cohen's approval rating as Axonics Modulation Technologies' CEO?

12 employees have rated Axonics Modulation Technologies CEO Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among Axonics Modulation Technologies' employees.

Who are some of Axonics Modulation Technologies' key competitors?

What other stocks do shareholders of Axonics Modulation Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics Modulation Technologies investors own include Raytheon Technologies (RTX), Honeywell International (HON), (OAS), Pfizer (PFE), The Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics Modulation Technologies IPO?

(AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley served as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics Modulation Technologies' stock symbol?

Axonics Modulation Technologies trades on the NASDAQ under the ticker symbol "AXNX."

Who are Axonics Modulation Technologies' major shareholders?

Axonics Modulation Technologies' stock is owned by many different institutional and retail investors. Top institutional investors include Credit Suisse AG (6.36%), BlackRock Inc. (5.73%), Lord Abbett & CO. LLC (3.82%), Bamco Inc. NY (3.22%), Hood River Capital Management LLC (1.32%) and Peregrine Capital Management LLC (1.18%). Company insiders that own Axonics Modulation Technologies stock include Alfred J Ford Jr, Alfred J Ford, Jr, Andera Partners, Bakker Juliet Tammenoms, Danny L Dearen, Geoff Pardo, John Woock, Michael V Williamson, Nancy Lynn Md Snyderman, Raphael Wisniewski, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends for Axonics Modulation Technologies

Which institutional investors are selling Axonics Modulation Technologies stock?

AXNX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Parian Global Management LP, Calamos Advisors LLC, Russell Investments Group Ltd., Kennedy Capital Management Inc., Peregrine Capital Management LLC, Castleark Management LLC, and Northern Trust Corp. Company insiders that have sold Axonics Modulation Technologies company stock in the last year include Alfred J Ford Jr, Alfred J Ford, Jr, Bakker Juliet Tammenoms, Danny L Dearen, John Woock, Raymond W Cohen, Rinda Sama, and Robert E Mcnamara.
View insider buying and selling activity for Axonics Modulation Technologies
or view top insider-selling stocks.

Which institutional investors are buying Axonics Modulation Technologies stock?

AXNX stock was purchased by a variety of institutional investors in the last quarter, including Credit Suisse AG, Hood River Capital Management LLC, Lord Abbett & CO. LLC, Columbus Circle Investors, Oak Ridge Investments LLC, Armistice Capital LLC, Magnetar Financial LLC, and Tri Locum Partners LP. Company insiders that have bought Axonics Modulation Technologies stock in the last two years include Nancy Lynn Md Snyderman, and Raymond W Cohen.
View insider buying and selling activity for Axonics Modulation Technologies
or or view top insider-buying stocks.

How do I buy shares of Axonics Modulation Technologies?

Shares of AXNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axonics Modulation Technologies' stock price today?

One share of AXNX stock can currently be purchased for approximately $52.87.

How much money does Axonics Modulation Technologies make?

Axonics Modulation Technologies has a market capitalization of $2.10 billion and generates $13.82 million in revenue each year. The company earns $-79,930,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

How many employees does Axonics Modulation Technologies have?

Axonics Modulation Technologies employs 302 workers across the globe.

What is Axonics Modulation Technologies' official website?

The official website for Axonics Modulation Technologies is www.axonics.com.

Where are Axonics Modulation Technologies' headquarters?

Axonics Modulation Technologies is headquartered at 26 TECHNOLOGY DRIVE, IRVINE CA, 92618.

How can I contact Axonics Modulation Technologies?

Axonics Modulation Technologies' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The company can be reached via phone at 949-396-6322 or via email at [email protected]

This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.